Since PD-L1 ligands are expressed on tumor cells in an inflammatory environment and as an important mechanism of immunoescape, PD-1/PD-L1 blockade therapy primarily act at the tumor site to overcome tumor-induced suppression of immune cells. The gene discussed is CD274; the disease is neoplasm.